Theradiag: US Launch of the Fifth Test in the LISA TRACKER® Range

LISA TRACKER®, the leading biotherapy monitoring range available in the global market

CROISSY-BEAUBOURG, France & MONTPELLIER, France--()--Regulatory News:

Theradiag (Paris:ALTER) (ISIN: FR0004197747, ticker: ALTER, eligible for PEA-PME equity savings plans in France), a company specializing in in vitro diagnostics and theranostics, is today announcing the launch of its Stelara® (ustekinumab) monitoring test in the US market, as part of its partnership with Miraca Life Sciences.

Theradiag's Stelara® monitoring kit expands Miraca Life Sciences' InformTxTM service in the US market, allowing monitoring of biotherapies for the treatment of inflammatory bowel disease (IBD).

InformTxTM is the only service of its kind in the USA, and now features five Theradiag monitoring tests. Miraca Life Sciences started marketing and promoting the service in June 20161, initially with four tests: Infliximab/Remicade®, Adalimumab/Humira®, Certolizumab/Cimzia® and Vedolizumab/Entyvio®.

“Increasing the number of drugs which we can test with our InformTx therapeutic drug monitoring allows us to provide critical information to help guide therapy for even more gastroenterologists and their patients,” said Richard Lash, MD, Chief Medical Officer and Executive Vice President of Operations for Miraca Life Sciences. “We plan to add more biologics to our InformTx testing service over time.”

"Miraca Life Sciences' US launch of our fifth monitoring test will broaden our offering in the US market, where twice as many patients are treated with biotherapies as in Europe, giving us us major sales potential in the next few years. Our LISA TRACKER® biotherapy monitoring range is the most comprehensive one currently available in the global market. Our ambition is to develop monitoring kits for all biotherapies on the market, both current and future, in our key therapeutic areas of expertise, i.e. autoimmune and inflammatory diseases, and also to offer them in the US market," added Michel Finance, CEO of Theradiag.

About Theradiag
Capitalizing on its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag notably markets the Lisa Tracker® range (CE marked), which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies. With its subsidiary Prestizia, Theradiag is developing new biomarkers based on microRNAs for the diagnosis and monitoring of rectal cancer, auto-immune and inflammatory diseases and HIV/AIDS. Theradiag is thus participating in the development of customized treatment, which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance. The Company is based in Marne-la-Vallée, near Paris, and in Montpellier, and has over 75 employees.

For more information about Theradiag, please visit our website: www.theradiag.com

1 See press release of June 16, 2016: “LISA TRACKER® launched in the US market”

Contacts

Theradiag
Investor Relations
Fabienne François, Tel.: +33 (0)1 64 62 10 12
CFO
contact@theradiag.com
or
NewCap
Financial Communications & Investor Relations
Valentine Brouchot, Tel.: +33 (0)1 44 71 94 94
theradiag@newcap.eu
or
Alize RP
Press Relations
Caroline Carmagnol / Florence Portejoie
Tel.: +33 (0)1 44 54 36 64
theradiag@alizerp.com

Release Summary

US launch of the fifth test in the LISA TRACKER® range.

Contacts

Theradiag
Investor Relations
Fabienne François, Tel.: +33 (0)1 64 62 10 12
CFO
contact@theradiag.com
or
NewCap
Financial Communications & Investor Relations
Valentine Brouchot, Tel.: +33 (0)1 44 71 94 94
theradiag@newcap.eu
or
Alize RP
Press Relations
Caroline Carmagnol / Florence Portejoie
Tel.: +33 (0)1 44 54 36 64
theradiag@alizerp.com